Received Mar 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | Unknown | PO / MO |
The patient received the second dose of Vivotif vaccine on 11-Apr-2024 and forgot the third and fourth dose; Case reference number US-BN-2024-001806 is a spontaneous case report initially received from a nurse via Med Communications (reference number: USBAV24-0765) on 16-Apr-2024 and concerns an 18-year-old male patient. The patient's medical history and concomitant medication details were not provided. On 09-Apr-2024, the patient took the first dose of Vivotif vaccine (batch number: unknown), at unknown dose, orally, for immunization against disease caused by Salmonella typhi. On 11-Apr-2024, two days after the first dose of Vivotif, the patient took the second dose of Vivotif vaccine (batch number: unknown), at unknown dose, orally. As reported, the patient forgot the third and the fourth dose of Vivotif vaccine and it has been four or five days (explicitly coded as 'missed dose'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif vaccine. No further information was provided.; Reporter's Comments: An 18-year-old male patient forgot the third and the fourth dose of Vivotif vaccine after the patient took the first and the second dose of Vivotif vaccine for immunization against disease caused by Salmonella typhi, and it has been four or five days, which is considered as missed dose. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Product dose omission issue is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product dose omission issue has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: An 18-year-old male patient forgot the third and the fourth dose of Vivotif vaccine after the patient took the first and the second dose of Vivotif vaccine for immunization against disease caused by Salmonella typhi, and it has been four or five days, which is considered as missed dose. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Product dose omission issue is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product dose omission issue has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None